MaxCyte’s stock is traded on the London Stock Exchange’s AIM market. Our Investor Relations web pages are not available to users from the U.S. U.S. securities regulations that provided an exemption from U.S. registration of its overseas offering require MaxCyte to ensure, for a period following its sale of stock overseas, that it does not promote the purchase of such stock by U.S. persons. We look forward to when this restriction is no longer applicable, and in the meantime, we regret that we are unable to provide you with access to this section of our website.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter